Adebelimab

Phase 2Monoclonal antibody

Shanghai Hengrui Pharmaceutical Co., Ltd.

Adebelimab is one of 139 small molecule programs targeting Malignant Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

138

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant Solid TumorsRecruiting

Advanced Solid TumorsRecruiting

Non-Small Cell Lung CancerRecruiting

Cervical CancerRecruiting

Malignant Solid TumorsPhase 1

Recruiting

Advanced Solid TumorsPhase 2

Recruiting

Non-Small Cell Lung CancerPhase 2

Recruiting

Cervical CancerPhase 2

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

HLX43

Shanghai Henlius Biotech

Phase 3

3 2

Cis Platinum

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

2 3

Adebelimab

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 2

1 4

Remeron

OOrganon and Co

Preclinical

1 5

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Cervical Cancer

NCT06859775

Q4 2027

Phase 1Recruiting

Malignant Solid Tumors

NCT07348042

Q4 2028

Phase 2Recruiting

Advanced Solid Tumors

NCT06895928

Phase 2Recruiting

TNBC, Triple Negative Breast Cancer

NCT07638852

Q2 2029

Phase 2Not yet recruiting

Endometrial Cancer

NCT06771154

Clinical

Trials by Indication[1]

Malignant Solid Tumors1 trial

Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors

Recruiting·XXian-Jun Yu·Phase 1·NCT07348042·198 enrolled

Advanced Solid Tumors1 trial

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

Recruiting· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 2·NCT06895928·400 enrolled

Cervical Cancer1 trial

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

Recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 1/2·NCT06859775·100 enrolled

Endometrial Cancer1 trial

Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial

Not yet recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06771154·140 enrolled

Non-Small Cell Lung Cancer1 trial

A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 1/2·NCT06589778·124 enrolled

1 more indication

TNBC, Triple Negative Breast Cancer1 trial

A Prospective, Two-arm, Multi-centre, Phase II Clinical Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of Patients With Brain Metastasis From Triple-Negative Breast Cancer

Recruiting·FFudan University·Phase 2·NCT07638852·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Adebelimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Adebelimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Adebelimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Hengrui Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: Shanghai Hengrui Pharmaceutical Co., Ltd.

Adebelimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q4 2028

Q2 2029

Trials by Indication[1]

Malignant Solid Tumors1 trial

Advanced Solid Tumors1 trial

Cervical Cancer1 trial

Endometrial Cancer1 trial

Non-Small Cell Lung Cancer1 trial

TNBC, Triple Negative Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News